Levoleucovorin

DRUG11 trials

Sponsors

Unicancer, Children's Oncology Group, Fujian Cancer Hospital, Asan Medical Center, Merck Sharp & Dohme LLC

Conditions

Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaColonic NeoplasmsColorectal NeoplasmsEsophageal AdenocarcinomaEsophageal Adenocarcinoma (EAC)Esophageal Cancer

Phase 1

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

RecruitingNCT06469944

Merck Sharp & Dohme LLCEsophageal Cancer, Esophageal Neoplasms, Gastroesophageal Adenocarcinoma +1

Start: 2024-09-20End: 2029-09-12Target: 160Updated: 2026-04-02

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

RecruitingNCT06780111

Merck Sharp & Dohme LLCEsophageal Squamous Cell Carcinoma

Start: 2025-07-30End: 2032-01-04Target: 298Updated: 2026-03-31

Phase 2

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

WithdrawnNCT03222089

Fujian Cancer HospitalMetastatic Colorectal Cancer

Start: 2017-07-20End: 2020-07-20Updated: 2018-03-27

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

CompletedNCT03698461

Asan Medical CenterColonic Neoplasms, Colorectal Neoplasms, Neoplasm Metastasis +1

Start: 2019-05-15End: 2023-10-24Updated: 2024-01-31

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Active, not recruitingNCT05945823

Taiho Oncology, Inc.Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer +2

Start: 2023-07-13End: 2027-01-31Updated: 2025-12-29

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RecruitingNCT06317662

National Cancer Institute (NCI)Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia

Start: 2025-06-05End: 2028-12-31Target: 153Updated: 2026-04-03

LOGICAN : Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2 negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma

RecruitingCTIS2024-512999-35-00

Unicanceroesophagus or gastroesophageal junction adenocarcinoma, Patients with HER 2 negative locally advanced, recurrent or metastatic gastric

Start: 2023-06-23Target: 118Updated: 2025-12-11

Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active, not recruitingNCT03007147

Children's Oncology GroupAcute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia +1

Start: 2017-08-08End: 2027-09-30Target: 475Updated: 2026-02-23

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Active, not recruitingNCT04210115

Merck Sharp & Dohme LLCEsophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)

Start: 2020-02-28End: 2027-02-01Target: 703Updated: 2024-11-15

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Active, not recruitingNCT04949256

Merck Sharp & Dohme LLCMetastatic Esophageal Squamous Cell Carcinoma

Start: 2021-07-28End: 2026-06-12Updated: 2025-12-15

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

RecruitingNCT05253651

Seagen, a wholly owned subsidiary of PfizerColorectal Neoplasms

Start: 2022-10-24End: 2029-07-27Target: 400Updated: 2026-03-16

Related Papers

Increased incidence of delayed methotrexate elimination in pediatric patients with Philadelphia-chromosome positive (Ph+) or ABL-class fusion positive (ABL-Class) acute lymphoblastic leukemia treated with imatinib: Results of a retrospective cohort study by the italian association of pediatric hematology-oncology (AIEOP)

Blood2025-11-03

KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).

Journal of Clinical Oncology2025-05-28

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma.

Journal of Clinical Oncology2025-01-27

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer

Future Oncology2024-12-2610 citations

Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer

Clinical Pharmacokinetics2024-10-012 citations

Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).

Journal of Clinical Oncology2024-06-013 citations

LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma

Future Oncology2024-05-024 citations

Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.

Journal of Clinical Oncology2024-01-202 citations

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.

Journal of Clinical Oncology2023-06-012 citations

Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer

Frontiers in Immunology2023-05-1914 citations

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.

Journal of Clinical Oncology2023-01-2418 citations

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial

Frontiers in Oncology2022-07-1329 citations

First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.

Journal of Clinical Oncology2022-06-012 citations

LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.

Journal of Clinical Oncology2022-01-195 citations

KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma

Future Oncology2021-02-03121 citations